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OVER the past decade, much has been learned
regarding the role of various cytokines in the
pathogenesis of in￿ ammatory bowel disease. Sev-
eral cytokine ‘knockout’ models in mice have
been shown to develop colitis, while alterations
in the production of various cytokines has been
documented in human Crohn’s disease and ul-
cerative colitis. In recent years, attempts have
been made to treat these diseases through mod-
ulation of cytokine production or action. This
review focuses on the cytokines that have been
implicated in the pathogenesis of in￿ ammatory
bowel disease. The evidence for and against a role
for particular cytokines in intestinal in￿ amma-
tion is reviewed, as is the experimental and
clinical data suggesting that cytokines are rational
targets for the development of new therapies.
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Introduction
‘In￿ammatory bowel disease’ (IBD) is an um-
brella term used to describe at least two distinct
diseases: ulcerative colitis (UC) and Crohn’s
disease (CD). UC and CD are chronic in￿amma-
tory conditions affecting the gastrointestinal
tract and are typi￿ed by unpredictable periods
of remission and relapse. UC affects the large
intestine and is usually limited to the mucosal
layer. CD is a transmural disease (extending to
the depth of the muscularis externae) and can
occur anywhere in the gastrointestinal tract,
although it most frequently affects the terminal
ileum and large intestine.
Current treatment of IBD, which is modestly
effective at best, primarily involves the use of
corticosteroids, 5-amino salicylic acid, and to a
lesser extent, immunosuppressants and anti-
microbials. The pathogenesis of IBD remains
poorly understood, hampering efforts to devel-
op more effective treatments. It is generally
believed that an impaired mucosal immune
response to luminal microbes leads to an
unrelenting in￿ammatory response with the
generation of non-speci￿c ‘bystander’ injury to
the intestinal tissue. Considerable research in
recent years has been directed at further under-
standing the mechanisms involved in regulating
the in￿ammatory response in IBD. Several
mediators are thought to play a role in this
response and/or to contribute to the tissue
injury and generation of symptoms, including
nitric oxide, histamine, eicosanoids and cyto-
kines. Given the key role of several cytokines in
regulating mucosal immune responses, this
family of mediators has received special atten-
tion by IBDresearchers in the past decade. This
review focuses on the emerging evidence for a
role for various cytokines in the pathogenesis of
IBD, and the possibility that these mediators
represent rationale targets for therapeutic inter-
vention. These cytokines can be divided into
two categories: those that upregulate and those
that downregulate the in￿ammatory response.
Pro-in¯ ammatory Cytokines
Interleukin-1 (IL-1)
IL-1 is released early in the in￿ammatory cas-
cade and has numerous pro-in￿ammatory ac-
tions (Table 1). IL-1 is produced by a wide array
of cells, including macrophages, monocytes,
endothelial cells and ￿broblasts.1 Two receptors
for IL-1 have been identi￿ed. Type I receptors
are found primarily on T lymphocytes and
￿broblasts, while type II receptors have been
identi￿ed on B lymphocytes, macrophages and
monocytes.1 IL-1 receptor antagonist (IL-1ra) is
a naturally occurring antagonist to both IL-1
receptors that is produced by many of the same
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determined by the balance between its levels
and those of IL-1ra at any target cell or tissue.1
Elevated levels of IL-1 activity in plasma and
tissue have been demonstrated in both CD and
UC, as well as in several experimental models of
colitis.2 9 Furthermore, the ratio of IL-1:IL-1ra is
increased in CD and UC but not in self-limited
colitis8 (Fig. 1). The pivotal role of IL-1 and IL-
1ra in regulating colonic in￿ammation has been
demonstrated by the observation that adminis-
tration of recombinant IL-1ra attenuates the
in￿ammatory process in three different animal
models of colitis. 10 12 The importance of IL-1ra
was further demonstrated in a rabbit model of
immune-complex colitis, where in￿ammation of
the colon was exacerbated by the administra-
tion of neutralizing antibodies directed against
IL-1ra13 (Fig. 2).
Sher et al. found that in patients with CD, IL-
1 and IL-8 levels were elevated in in￿amed and
normal colonic tissue.14 Thus, cytokine activa-
tion may occur prior to the development of
macroscopically visible damage or may simply
involve the entire region of the gut when only
limited macroscopic disease exists. A similar
pattern was also noted in pouchitis (in￿amma-
tion of a surgically constructed ileal reservoir).
Levels of IL-1, IL-6 and IL-8 were increased in
pouchitis, but levels of IL-1 and IL-8 were also
increased in non-in￿amed pouches relative to
normal ileal mucosa.15
Table 1. Actions of pro-in¯ ammatory cytokines and relevance to IBD
Cytokine Actions on cells and mediators Relevance to IBD
IL-1 Promotes Increased levels in UC, CD and pouchitis and in animal
· T cell activation models of colitis
· NK cell activation Experimental colitis can be improved by treatment
· B cell proliferation with IL-1 receptor antagonist and exacerbated by
Upregulates treatment with an antibody to
· adhesion molecule expression IL-1 receptor antagonist
· eicosanoid and nitric oxide production
IL-2 Promotes IL-2 knockout mice develop colitis
· Th1 lymphocyte activation Abnormal IL-2-induced T cell proliferation in UC
· macrophage activation Decreased IL-2 levels in UC
· intraepithelial lymphocyte proliferation Increased IL-2 mRNA in CD, not UC
IL-5 Promotes Increased IL-5 mRNA in CD, increased IL-5 production in UC
· eosinophil recruitment and differentiation
IL-6 Promotes Increased IL-6 levels in UC, CD and pouchitis
· activation of T cells Levels of IL-6 correlate with disease activity and may
· differentiation of B cells predict relapses of CD
· induction of hepatic acute phase reactants
IL-8 Promotes Increased IL-8 levels in UC, CD and pouchitis
· neutrophil recruitment and activation
IL-12 Promotes Increased IL-12 levels in IBD (CD . UC)
· natural killer cell and cytotoxic T
lymphocyte activity
TNFa Promotes Increased TNFa levels in UC and CD
· leukocyte adherence (through elevated
adhesion molecule expression)
Anti-TNFa antibodies reduce in¯ ammation in CD
· activation of neutrophils, eosinophils,
macrophages, lymphocytes
IFNa Promotes Increased IFNa mRNA in lamina propria cells from
· MHC expression CD patients
· NK and antibody-dependent cytotoxicity IFNa therapy for CD appears to be of little bene® t
· macrophage activation
Inhibits
· cell growth and differentiation
Abbreviations: NK, natural killer; MHC, major histocompatability complex; UC, ulcerative colitis; CD, Crohn’s disease; IBD, in¯ ammatory bowel
disease.
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FIG. 1. Ratio of IL-1 receptor antagonist (IL-1ra) to IL-1 levels
in mucosal biopsies from normal individuals, patients with
self-limiting (S-L) colitis, Crohn’s disease (CD) and ulcera-
tive colitis (UC). The ratio is signi® cantly ( P , 0 01)
depressed in patients with UC and CD relative to the other
two groups. Prepared using the data Casini-Raggi et al.
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with permission of the authors.
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appears promising. Cominelli and co-workers16
reported that an inhibitor of IL-1 and TNFa
synthesis (CGP 47969A) signi￿cantly decreased
the severity of in￿ammation in a rabbit model
of colitis. Clinical trials of recombinant IL-1ra
were initiated a number of years ago, but were
not completed due to disappointing results
from trials of this cytokine unrelated to IBD. For
several years, nicotine has been suggested to
decrease activity in UC and recently it has been
found to be effective in the treatment of active
UC (but not in the maintenance of re-
mission).17,18 The mechanism of action of nico-
tine in the treatment of UC is not well
understood, but it has been suggested to be due
to its ability to suppress the production of IL-1
and TNFa.19
Interleukin-2 (IL-2)
IL-2 is a key factor in the regulation of T
lymphocyte proliferation.1 It also in￿uences
proliferation of B lymphocytes and natural killer
(NK) cells. High and low af￿nity receptors for
IL-2 have been identi￿ed on several cells.1 3 IL-
2 levels and IL-2 responses are increased in CD,
but decreased in UC.20,21 In peripheral blood
monocytes isolated from paediatric patients
with IBD, indomethacin increased IL-2 produc-
tion in monocytes from CD patients but not in
those from UC patients.22 A potential role of IL-
2 in the pathogenesis of IBD was suggested
when two patients with CD received high-dose
IL-2 for the treatment of renal cell carcinoma23
and both experienced a ￿are in CD symptoms
requiring immediate bowel resection.23
In terms of IL-2-related therapy, cyclosporin
A, FK506, and rapamycin are all inhibitors of
lymphocyte activation and decrease IL-2 syn-
thesis and/or IL-2 responsiveness. Cyclosporin A
has been shown to exhibit some ef￿cacy in the
treatment of IBD,24,25 while FK506 has shown
promise in an animal model of colitis.26
Interleukin-5 (IL-5)
IL-5 is among the most potent chemotaxins for
eosinophils yet described, and can enhance
immunoglobulin A secretion by B lympho-
cytes.1 3 In a study looking at early recurrence
of CD following resection, Dubucquoi et al.
found that eosinophil in￿ltration was more
pronounced in areas with endoscopically visible
disease compared with normal-appearing tissue,
and that increased numbers of eosinophils were
associated with elevated IL-5 mRNA expres-
sion.27 However, more direct evidence for a role
of IL-5 in IBDis lacking.
Only one study has examined the role of IL-5
in experimental colitis, yielding results that
were inconclusive. The severity of dextran
sulphate sodium-induced colitis in mice in
which the gene for IL-5 had been deleted (IL-5
knock-out mice) was found not to differ from
that in normal mice.28 Given the high likelihood
that there is redundancy in terms of the number
of mediators that can produce the pro-in￿amma-
tory effects ascribed to IL-5, and that there may
be up-regulation of the production of these
other mediators as a means of compensating for
the lack of IL-5 in the knock-out mice, one
cannot draw any ￿rm conclusions from this
study regarding the role of IL-5 in colitis.
Interleukin-6 (IL-6)
IL-6 appears to be one of the most important
cytokines in the in￿ammatory response. The
main actions of IL-6 include activation of Tand
B lymphocytes and induction of hepatic acute
phase reactants.29 Previous studies noted eleva-
tions of IL-6 in both CD and UC and more
recently in pouchitis.3,14,15,30 Serum levels of IL-6
and soluble IL-6 receptor as well as tissue levels
of IL-6 appear to correlate well with disease
activity in both CD and UC.31,32 Recently, a
group from Belgium found that serum IL-6
levels in patients with inactive CD, followed for
one year, correctly predicted whether a patient
would relapse in 29 of 32 cases.33
Interleukin-8 (IL-8)
IL-8 is a potent chemotaxin for neutrophils.1 3
Increased IL-8 levels have been demonstrated in
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FIG. 2. Effects of treatment with an antibody directed
against IL-1 receptor antagonist (IL-1ra) on severity of
chronic in¯ ammation in a rabbit model of colitis. Treatment
with anti-IL-1ra signi® cantly increased the severity of colitis
relative to rabbits treated with a control antibody or to
healthy rabbits receiving only saline ( P , 0 03) Prepared
using the data of Cominelli et al.
13
with permission of the
authors.
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correlated with disease activity.15,34 These stud-
ies were recently con￿rmed by Patel et al. and
Sher et al., who also reported elevated levels of
IL-8 in non-in￿amed tissue from ileoanal
pouches and CD.14,30 The role of IL-1 and TNFa
in regulating IL-8 in colitis was demonstrated by
Cominelli’s group in the study referred to
above.16 They found that an inhibitor of the
synthesis of IL-1 and TNFa (CGP 47969A)
reduced the severity of damage in a rabbit
model of colitis and this reduction of damage
was associated with decreased colonic IL-1 and
IL-8 levels.16
IL-8 production by isolated colonic crypt cells
is increased in IBD.35 The short chain fatty acid
butyrate was shown to signi￿cantly reduce IL-8
secretion from these cells, possibly explaining
the ef￿cacy of short chain fatty acids in the
treatment of distal UCand diversion colitis.35
Tumour necrosis factor-a (TNFa)
Like IL-1, TNFa is released from macrophages
early in the in￿ammatory response. TNFa has
numerous roles in the in￿ammatory cascade
and has been implicated in the pathogenesis of
IBD(T able 1). Numerous studies have documen-
ted marked elevations TNFa in CD, UC and
pouchitis.3,8,14,30,36 38 Tissue, serum and intra-
luminal concentrations of TNFa have been
shown to correlate with disease activity in both
UC and CD.3,36,37 Soluble TNFa receptors
(sTNF-R), p55 and p75, have previously been
shown to be elevated in the serum of patients
with CD.39 More recently, p55 and p75 were
noted to be elevated in the urine of patients
with either CD or UC, and these levels closely
correlated with disease activity.40 Thus, it is
possible that intraluminal, serum or urine levels
of TNFa or sTNF-R may aid in assessing and
managing the IBDpatient.
Recently, therapy aimed at regulation of TNFa
activity has been evaluated. A single administra-
tion of an anti-TNFa monoclonal antibody (cA2)
was found to be ef￿cacious in 10 patients with
CD who were resistant to conventional
therapy.41 In this open label, uncontrolled study,
the mean disease severity (CD activity index)
had decreased by 55%at 2 weeks and by 73%at
8 weeks following therapy. Endoscopy at 4
weeks’ post-cA2 infusion showed near-complete
healing of all ulceration. The average duration
of response following a single dose of cA2 was
4 months. The extraintestinal manifestations of
IBD (two with arthritis and one with pyoderma
gangrenosum) also improved dramatically fol-
lowing cA2 administration. A marked reduction
of IL-6 and C-reactive protein levels was ob-
served, with the levels remaining below base-
line values for up to 6 weeks following cA2
administration. 41 In a smaller study (￿ve pa-
tients), clinical improvement of CD following
treatment with cA2 appeared to correlate with
a reduction in levels of cytokines associated
with Th1 lymphocytes.42
A different form of anti-TNFa antibody
(CDP571) was also recently evaluated. Two
weeks following a single administration of
CDP571, the mean CD activity index had de-
creased from 263 to 167, with six of the 15
patients achieving ‘remission’ (de￿ned as a CD
activity index of less than 150).43
A multicentre trial of cA2 is presently under-
way. In preliminary studies, a single dose of 1 to
20 mg/kg induced a signi￿cant clinical response
in 18 of 20 patients. The dose given did not
affect the likelihood of response, but the dura-
tion of the response appeared to be dose-
dependent.44 A role for cA2 in the treatment of
UC remains equivocal at this stage. There has
been one report of this antibody being effective
in steroid-refractory UC,45 while in another
study cA2 was found to have no effect on
reducing the severity of colonic in￿ammation in
UC.46
The main criticisms of the studies performed
to date using anti-TNFa antibodies are the small
sample size and, from a mechanistic point of
view, how a single infusion of cA2 can have
such long-lasting effects. There are some indica-
tions that anti-TNFa antibodies may cause a
reduction in speci￿c lymphocyte subsets and
thus may act by destroying these cells rather
than blocking TNFa. Interestingly, similar re-
sults have been noted with the use of cA2 in
the treatment of rheumatoid arthritis.47
Interferons (IFN)
Interferons a, b and c are part of a family of
secreted proteins with potent antiproliferative
and immunomodulatory activities.1 3 Mono-
nuclear cells isolated from the lamina propria of
CDpatients have been shown to have increased
levels of both IFNc and IFNa mRNA.48 Since
there have been reports of both improvement
and exacerbation of IBD in patients undergoing
IFNa therapy for other illnesses, two studies
addressed the use of IFNa in CD. Davidsen et
al. reported that only two of ￿ve CD patients
treated with IFNa had signi￿cant reductions
in the severity of their disease and all had
in￿uenza-like symptoms related to therapy.49
Gasche et al. found that in a group of 12
patients with CD that received IFNa and pred-
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for another 12 weeks, none achieved remission
and 66% of patients had be withdrawn from
trial prematurely.50 IFNa therapy was associated
with signi￿cant side effects, failed to show any
bene￿cial effect on serum IL-6 and acute phase
protein levels and did not decrease the endo-
scopic severity of the disease.50 Thus, based on
the results from these two small studies, there
does not appear to be any therapeutic role for
IFNa in the treatment of CD.
Anti-in¯ ammatory Cytokines
The main anti-in￿ammatory cytokines include
IL-1ra, IL-4, IL-10, IL-11, IL-13 and TGF-b (T able
2). IL-1ra has been discussed above.
Interleukin-4 (IL-4)
IL-4 is primarily produced by mast cells and T
lymphocytes. This cytokine has numerous ac-
tions as noted in Table 2, including the ability
to down-regulate IFNc, IL-1 and TNFa produc-
tion and stimulate IL-1ra and IL-10 synthesis.1,2,51
Recently it has been suggested that there is a
defect in the ability of IL-4 to regulate the
in￿ammatory response in IBD. Schreiber et al.
noted that approximately 100-fold higher levels
of IL-4 were required to inhibit monocyte
production of IL-1b, TNFa and superoxide
anion in patients with CDor UCcompared with
controls. IL-4 production by T -cells and the
expression of IL-4 receptors by monocytes were
reduced in patients with UC or CD. This could
lead to impaired IL-4 responsiveness in these
patients.51,52
Interleukin-10 (IL-10)
In humans IL-10 is mainly produced by Th2
cells but it can also be produced by both Th1
cells and monocytes. 53 56 IL-10 has numerous
actions but its main role appears to involve
inhibition of macrophage and T cell function
(Table 2).53,56 There have been con￿icting
reports on IL-10 levels in IBD. In some studies
IL-10 was found to be elevated in UC but not
CD, suggesting UChad a Th2 pattern (increased
IL-4, IL-5, IL-6 and IL-10) of cytokine activation
whereas CD displayed a Th1 pattern (increased
IL-2 and IFNc).1,2,53 Kucharzik et al. noted that
IL-10 was elevated in the serum of patients with
either UC or CD, and the levels of IL-10
correlated well with disease activity.53 There
was no difference in the serum levels of IL-10
from those with active UCcompared with those
with active CD.53 The only difference noted was
that IL-10 levels correlated well with serum IL-6
and soluble IL-2 receptor levels in those with
Table 2. Actions of anti-in¯ ammatory cytokines and relevance to IBD
Cytokine Actions on cells and mediators Relevance to IBD
IL-1ra Endogenous receptor antagonist of IL-1 Reduced severity of colitis in experimental model
Ratio of IL-1 to IL-1ra production is elevated in active UC
and CD
IL-4 Promotes Decreased responsiveness of monocytes to IL-4 in CD
· mast cell growth and UC
· IgE production Decreased IL-4 receptor expression in UC and CD
· IL-1ra and IL-10 synthesis
Inhibits
· TNFa and IFNc synthesis
IL-10 Inhibits IL-10 knockout mice develop enterocolitis
· TNFa, IL-1, IL-2, IL-6, IL-8, IFNc and nitric
oxide production
IL-10 reduced severity of experimental colitis
· macrophage and T lymphocyte function
IL-11 Promotes Reduces in¯ ammation in several experimental models of
· neutrophil, erythrocyte and platelet
production
colitis
· proliferation and differentiation of small
intestinal crypt cells
IL-13 Downregulates Reduces severity of experimental colitis and eicosanoid
· monocyte production of IL-1, IL-6, IL-8 and
TNFa
production
TGFb Promotes Increased TGF-b levels in IBD
· wound healing, epithelial restitution TGF-b knockout mice develop colitis
· IL-1ra synthesis
Inhibits
· nitric oxide synthesis
· TNFa, IFNc synthesis
· leukocyte rolling (E selectin expression)
Abbreviations: UC, ulcerative colitis; CD, Crohn’s disease; IBD, in¯ ammatory bowel disease.
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10 regulation is signi￿cantly different in CD
versus UC was further disputed by the ￿ndings
of Schreiber et al.55 They found no difference in
the tissue concentrations of IL-10 in patients
with CD versus those with UC.55 It was also
noted that the IL-10 downregulation of TNFa
and IL-1b secretion by peripheral monocytes
was similar in patients with IBD and normal
controls. 55 As noted above, patients with IBD
have an abnormal IL-1:IL-1ra ratio in favour of
increased IL-1 activity. In the study by Schrei-
ber’s group, the addition of IL-10 to either
peripheral monocytes or intestinal macrophages
from patients with IBDcould restore the IL-1:IL-
1ra ratio to that found in cell suspensions from
normal controls.55 Thus, it was hypothesized
that IL-10 regulation was intact in IBD and that
there was not a true de￿ciency of IL-10, but
there may be a de￿ciency of IL-10 relative to
the degree of in￿ammation in IBD. Schreiber et
al. treated three patients with active UC with
IL-10 enemas and all exhibited marked reduc-
tions in TNFa and IL-1b secretion, but only a
minimal reduction in stool frequency and endo-
scopic scores.55 A multicentre trial of the use of
IL-10 in CDis presently underway.
There is emerging evidence from animal
models for a key role of IL-10 in the mainten-
ance of intestinal mucosal integrity and mucosal
immune function. Mice in which the gene for
IL-10 has been deleted exhibit profound entero-
colitis, which can be prevented through admin-
istration of recombinant IL-10.54 IL-10 can also
reduce the severity of colitis in a number of
experimental models, although there appears to
be some variation in the responsiveness of each
model and of the dose required to achieve a
signi￿cant effect. 57 59 IL-10 has also recently
been shown to prevent secretagogue-induced
epithelial secretion in the rat small intestine,
suggesting that it might be an important factor
in limiting the development of diarrhoea.60
Interleukin-11 (IL-11)
IL-11 was originally isolated from bone marrow
stromal cell lines and was found to have both
haematopoietic and non-haematopoietic regula-
tory actions.61,62 IL-11 receptor belongs to the
same family of cytokine receptors as that for IL-
6. Both IL-6 and IL-11 stimulate T cell-depen-
dent B cell maturation and enhance platelet and
myeloid cell differentiation.61,62 The mechanisms
involved in the anti-in￿ammatory actions of IL-
11 are not well understood. It has been found
to decrease to the severity of intestinal damage
following irradiation, cytoablative drugs or ex-
posure to Clostridium dif￿cile toxin A.63 65 IL-
11 has also been found to decrease the severity
of in￿ammation in the TNBS, acetic acid and
transgenic HLA-B27 models of colitis. 66 68 The
role of IL-11 in the in￿ammatory response in
UCand CDhas yet to be determined.
Interleukin-13 (IL-13)
IL-13 is a lymphocyte-derived cytokine that
appears to have some immunosuppressive ac-
tions that are similar to IL-4 and IL-10. IL-13
downregulates the release of IL-1b, IL-6, IL-8
and TNFa from monocytes, and also induces
the expression of vascular cell adhesion mole-
cule (VCAM-1). On the other hand, IL-13 can
inhibit IFN-induced upregulation of intercellular
adhesion molecule-1 (ICAM-1). 69 73 Nitric oxide
(NO) synthesis and inducible nitric oxide
synthase (iNOS) are increased in the colonic
epithelium of patients with UC.74 In a recent
study using a human colonic epithelial cell line,
IL-13 downregulated NO release and iNOS ex-
pression but IL-10 had no effect.75 Both IL-4 and
IL-13 have been reported to suppress cyclooxy-
genase-2 expression in osteoblasts, but this
interaction has not been studied in the gut.70 In
peripheral monocytes isolated from IBD pa-
tients the ability of IL-13 to inhibit the produc-
tion of pro-in￿ammatory cytokines was reduced
compared with cells from control patients or
from patients with inactive IBD.76 Interestingly,
it appears that IL-10 can act synergistically with
IL-4 or IL-13 to downregulate pro-in￿ammatory
cytokine production by peripheral blood mono-
cytes in IBD, suggesting that combined immuno-
suppressive cytokine therapy may be
bene￿cial.77 IL-13 is also produced by activated
mast cells, but the implications of this to IBD
has yet to be studied.78
Transforming growth factor-b (TGF-b)
TGF-b is a cytokine with several anti-in￿amma-
tory properties, including modulating the func-
tion and secretory activity of macrophages and
other immunocytes.1 TGF-b is also a promoter
of wound healing.1 There appears to be a
signi￿cant upregulation of TGF-b release in
patients with IBD and following intestinal irra-
diation (Table 2).1,79 82 TGF-b can downregulate
intestinal cell proliferation and promote cellular
differentiation.80 TGF-b can also modulate the
production of other cytokines, particularly IL-
1ra (increased), IL-1, TNFa and IFN-c (de-
creased), 83 can suppress nitric oxide production
by macrophages84 and can reduce leukocyte
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ing expression of E-selectin.85
Mice in which the gene for TGF-b has been
deleted develop colitis, suggesting a key role for
this cytokine in the maintenance of mucosal
integrity and mucosal immune function.86 More
direct evaluation of the role of TGF-b in human
IBDhas not yet been performed.
Conclusions
While incompletely understood, the pathogen-
esis of IBDis generally believed to be related to
an improperly regulated mucosal immune re-
sponse to luminal microbes. As central regula-
tors of immune responses, the cytokine family
have been extensively studied in human IBD
and experimental models of colitis. The obser-
vation that severe in￿ammation of the small
and/or large intestine occurs spontaneously in
several mouse models in which the genes for
various cytokines have been deleted adds sup-
port to the hypothesis that perturbations in the
cytokine cascade could contribute to the
development of IBD. Clinical studies of IBD
have begun to reveal marked alterations in the
production of certain cytokines, or in the
responsiveness of immunocytes to various cyto-
kines. Ultimately, these studies may help to
identify potential targets for the therapy of
these diseases. Indeed, the early, very promising
results with antibodies directed against TNFa
suggest that cytokine-targeted therapy may in
the future become a mainstream treatment for
IBD, or at the very least, may be useful adjuncts
to existing therapies in the management of IBD
in certain subsets of patients.
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